L
La Jolla Pharmaceutical Company, a subsidiary of Innoviva, Inc., is dedicated to the commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. La Jolla markets GIAPREZA® (angiotensin II) injection and XERAVA® (eravacycline) for injection. For more information, please visit www.ljpc.com.
Investor insights
Funding rounds participated in
$111M sweet spot round size
Investor type
Privately Held
Basic info
Industry
Biotechnology Research
Sectors
Biotechnology Research
Date founded
1989
Funding rounds raised
Total raised
$111M
from investors over 1 rounds
L
La Jolla Pharmaceutical Company raised $111M on October 9, 2015